Recombinant ORF2 Enzyme Mutations for Cannabinoid Biosynthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing cannabinoids, such as Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), face challenges including plant susceptibility to climate and diseases, low content of less-abundant cannabinoids, and high production costs due to complex chemical synthesis and extraction processes.
Innovation Solution
Development of a recombinant polypeptide with specific amino acid substitutions that enhances the conversion of olivetolic acid and geranyl diphosphate to cannabigerolic acid and 5-geranyl olivetolate, offering higher production yields and ratios compared to wild-type enzymes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If chemical synthesis methods are used to produce cannabinoids, then production cost increases, but manufacturing precision and yield decrease
Solution Approach 1:
The patent replaces complex chemical synthesis mechanisms with a biological system using genetically engineered enzymes. The engineered ORF2 enzyme catalyzes the conversion of olivetolic acid and geranyl diphosphate to cannabigerolic acid through biological catalysis, substituting multiple chemical reaction steps with a single enzymatic step, thereby reducing production cost and improving yield simultaneously
2Ease of manufacture
If plant extraction methods are used to obtain cannabinoids, then simplicity of process is maintained, but productivity and content of less-abundant cannabinoids are low
Solution Approach 1:
The patent modifies the enzymatic parameters through site-directed mutagenesis, changing amino acid residues at specific positions (e.g., Q161S, Q295L, S214R mutations) to optimize enzyme activity and substrate specificity. This enhances the conversion efficiency and cannabinoid content while maintaining the simplicity of the extraction process
3Reliability
If wild-type enzymes are used for cannabinoid synthesis, then natural pathway is maintained, but productivity and selectivity are insufficient
Solution Approach 1:
The patent applies local quality modification by making specific point mutations at particular amino acid positions within the enzyme sequence while maintaining the overall structural integrity and natural pathway functionality. The mutations at positions 161, 214, and 295 locally enhance catalytic activity and substrate binding affinity, improving productivity without disrupting the natural biosynthetic pathway
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant polypeptide achieves higher production levels of cannabigerolic acid and 5-geranyl olivetolate, providing a cost-effective and environmentally friendly approach to synthesizing cannabinoids.
Implementation Method 1
the recombinant polypeptide converts olivetolic acid (OA) and geranyl diphosphate (GPP) to cannabigerolic acid (CBGA) and 5-geranyl olivetolate (5-GOA)
Data Source
AI summary
The disclosure relates to the biosynthesis of cannabinoids and related prenylated phenolic compounds using recombinant enzymes. In particular, the disclosure provides recombinant mutant ORF2 enzymes engineered to produce a greater amount of a desired product, or to have a greater ability to catalyze a reaction using a desired substrate, as compared to WT ORF2. The disclosure also provides methods of preparing such ORF2 mutant enzymes; as well as methods of use thereof in improving the biosynthesis of cannabinoids and related prenylated phenolic compounds.